Artificial intelligence a promising tool for improving early melanoma diagnosis
Digital photography combined with artificial intelligence technology has shown promising results as a diagnostic tool for the early detection of melanoma.
Featured News
Digital photography combined with artificial intelligence technology has shown promising results as a diagnostic tool for the early detection of melanoma.
A lived experience with cancer inspired Paul White and Mary Tsouvalakis to join the MASC Trials Board.
Originally diagnosed with a detached retina, a scan later revealed that Jess actually had ocular melanoma.
After a shock diagnosis that resulted in her losing an eye, Michelle found herself desperately seeking information about ocular melanoma. Now Michelle’s joined the Uveal Melanoma Registry, so others don’t have to encounter the lack of clarity that she did.
When we first featured the story of Bruno and his mission to complete a half-ironman while battling stage III melanoma, it struck a chord with many of our members and followers.
Australia and The Netherlands have an alarming statistic in common – melanoma is in their top five most diagnosed cancers. Clinical teams from both countries are now contributing to the international MelMarT-II trial.
As a retired primary school teacher, Viv has spent most of his adult life passing on valuable knowledge to his students. But it was a visit to his doctor that provided him with an unexpected – and lifesaving – lesson.
A community fundraising campaign has donated $100,000 to a clinical trial investigating melanoma that has spread to the brain.
MASC Trials and Melanoma Patients Australia have launched Self-Skin Checks, No Regrets, an Australian first campaign targeting rural and regional Australians 60+ to regularly check their skin.
An Australian-led trial is now gathering melanoma experts from around the world to contribute results from 3,000 patients to determine the optimal surgical excision margin for melanoma of the skin.